Results 271 to 280 of about 80,577 (303)
Some of the next articles are maybe not open access.
Zeitschrift fur Rheumatologie, 2013
Janus protein tyrosine kinase (JAK) inhibitors are new therapeutic targets in the treatment of rheumatoid arthritis. Tofacitinib has shown good clinical efficacy in phase II and III studies with American College of Rheumatology (ACR) 20 response rates over 50% for monotherapy and in combination with methotrexate (MTX).
E, Ostermeier, P, Roll, H-P, Tony
openaire +1 more source
Janus protein tyrosine kinase (JAK) inhibitors are new therapeutic targets in the treatment of rheumatoid arthritis. Tofacitinib has shown good clinical efficacy in phase II and III studies with American College of Rheumatology (ACR) 20 response rates over 50% for monotherapy and in combination with methotrexate (MTX).
E, Ostermeier, P, Roll, H-P, Tony
openaire +1 more source
Janus Activated Kinase inhibition in Myelofibrosis
Indian Journal of Cancer, 2012Janus Activated Kinase (JAK) 2 plays an important role in the pathogenesis of myelofibrosis (MF). Ruxolitinib (INCB018424, Jakafi) is a potent dual JAK1 and JAK2 inhibitor. In November 2011, it became approved by the US FDA for the treatment of intermediate or high-risk MF.
openaire +2 more sources
Thromboembolism and Janus Kinase Inhibitors
Drug Safety, 2020Fowzia Ibrahim, David L. Scott
openaire +3 more sources
Potential Use of Janus Kinase Inhibitors in the Treatment of Systemic Lupus Erythematosus
Journal of Inflammation Research, 2023Rongxiu Huo +2 more
exaly
Janus Kinase Inhibitors and Risk of Venous Thromboembolism: A Systematic Review and Meta-analysis
Mayo Clinic Proceedings, 2021Jawad Bilal +2 more
exaly
<p>Emerging Role of Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis</p>
ImmunoTargets and Therapy, 2020Rhea Singh +2 more
exaly